Journal of Diabetes Science and Technology,
Journal Year:
2024,
Volume and Issue:
unknown
Published: Dec. 31, 2024
Type
1
diabetes
(T1D)
necessitates
lifelong
insulin
therapy
due
to
the
autoimmune
destruction
of
insulin-producing
pancreatic
beta
cells.
Despite
advancements
in
technology
and
formulations,
maintaining
optimal
glycemic
outcomes
remains
challenging
these
individuals.
Obesity,
accompanied
by
resistance,
is
common
not
only
type
2
(T2D)
but
also
many
individuals
with
T1D.
Glucagon-like
peptide-1
receptor
agonists
(GLP-1
RAs),
approved
for
T2D
obesity,
are
now
being
explored
off-label
use
This
review
examines
their
efficacy,
safety,
potential
benefits
T1D
management.
We
reviewed
articles
published
up
May
2024
from
databases
like
PubMed
Scopus,
mainly
focusing
on
human
studies
GLP-1
RAs
T1D,
as
well
cardiorenal
metabolic
obesity.
Semaglutide
other
showed
significant
improvements
outcomes,
hemoglobin
A1c
levels,
reduced
doses,
notable
weight
loss.
Studies
obesity
lipid
profile
offered
protection.
Common
side
effects
include
gastrointestinal
issues,
while
some
reported
hypoglycemia,
hyperglycemia,
ketosis,
others
did
not.
challenges,
offer
therapeutic
benefits,
making
them
a
promising
adjunct
improving
clinical
BMJ,
Journal Year:
2025,
Volume and Issue:
unknown, P. e080679 - e080679
Published: Feb. 26, 2025
Abstract
Objective
To
determine
whether
the
use
of
glucagon-like
peptide-1
(GLP-1)
receptor
agonists
is
associated
with
an
increased
risk
suicidal
ideation,
self-harm,
and
suicide
among
patients
type
2
diabetes
compared
dipeptidyl
peptidase-4
(DPP-4)
inhibitors
or
sodium-glucose
cotransporter-2
(SGLT-2)
inhibitors.
Design
Active
comparator,
new
user
cohort
study.
Setting
Primary
care
practices
contributing
data
to
UK
Clinical
Practice
Research
Datalink
linked
Hospital
Episodes
Statistics
Admitted
Patient
Care
Office
for
National
Death
Registration
databases.
Participants
Patients
diabetes.
Exposures
Two
cohorts
were
assembled,
first
composed
who
started
continued
on
GLP-1
DPP-4
between
1
January
2007
31
December
2020
second
SGLT-2
2013
2020.
Both
followed
until
29
March
2021.
Main
outcome
measures
The
primary
was
suicidality,
defined
as
a
composite
suicide.
Secondary
outcomes
each
these
events
considered
separately.
Propensity
score
fine
stratification
weighted
Cox
proportional
hazards
models
fitted
estimate
hazard
ratios
95%
confidence
intervals
(CIs)
average
treatment
effect
treated
patients.
Results
included
36
082
agonist
users
(median
follow-up
1.3
years)
234
028
inhibitor
1.7
years).
In
crude
analyses,
incidence
suicidality
(crude
rates
3.9
v
1.8
per
1000
person
years,
respectively;
ratio
2.08,
CI
1.83
2.36).
This
decreased
null
value
after
confounding
factors
accounted
(hazard
1.02,
0.85
1.23).
32
336
1.2
96
212
Similarly,
in
analyses
4.3
2.7
years;
1.60,
1.37
1.87)
but
not
(0.91,
0.73
1.12).
Similar
findings
observed
when
analysed
separately
both
cohorts.
Conclusions
this
large
study,
Journal of Psychiatric Research,
Journal Year:
2025,
Volume and Issue:
183, P. 112 - 126
Published: Feb. 6, 2025
Reports
submitted
to
the
FDA
and
EMA
suggest
that
Glucagon-Like
Peptide-1
Receptor
Agonists
(GLP-1
RAs)
may
be
associated
with
an
elevated
risk
of
suicidality.
To
ascertain
this
association
across
available
pharmacovigilance
cohort
studies,
Pubmed,
Medline,
Cochrane
Library,
PsychInfo,
Embase,
Scopus,
Web
Science
were
searched
from
database
inception
November
20,
2024
in
accordance
PRISMA
guidelines.
A
manual
search
using
Google
Scholar
was
also
conducted
identify
additional
studies.
Cohort
studies
assessed
for
quality
Newcastle-Ottawa
Scale.
We
endeavored
define
operationalize
suicidality
as
suicide
ideation
(SI),
attempts
(SA),
completion
(SC),
cases
where
study
authors
failed
separate
these
three
dimensions,
term
"suicidality"
applied.
22
meeting
inclusion
criteria
comprised
(n
=
10)
12)
identified.
Pharmacovigilance
indicate
semaglutide
liraglutide
are
disproportionate
reporting
SI.
Results
GLP-1
RAs
not
consistently
increase
any
aspect
suicidality;
instead,
some
agents
decreased
SI
SA.
There
is
inadequate
information
whether
causality
exists
linking
Ongoing
vigilance
further
required
inform
if
possibility
exists.
Practitioners
prescribing
should
vigilant
emergence
aware
higher
mental
illness
persons
who
would
candidates
(e.g.
Type
2
Diabetes,
obesity).
Diabetes/Metabolism Research and Reviews,
Journal Year:
2025,
Volume and Issue:
41(2)
Published: Feb. 1, 2025
ABSTRACT
Background
and
Objective
Glucagon‐like
peptide‐1
receptor
agonists
(GLP‐1RAs)
are
widely
used
to
treat
type
2
diabetes
obesity,
providing
metabolic
cardiovascular
benefits.
However,
concerns
have
emerged
about
potential
neuropsychiatric
side
effects,
including
suicidal
ideation
behaviour,
prompting
investigations
by
regulatory
bodies
such
as
the
FDA
EMA.
This
systematic
review
meta‐analysis
aimed
assess
association
between
GLP‐1RA
use
risk
of
or
behaviour.
Methods
A
literature
search
was
conducted
in
PubMed,
Embase,
Web
Science
through
September
2024,
adhering
PRISMA
guidelines.
Observational
cohort
case‐control
studies
reporting
behaviour
adults
using
GLP‐1RAs
were
included.
The
Modified
Newcastle‐Ottawa
Scale
assessed
bias,
random‐effect
models
calculated
ratios
(RR)
with
95%
confidence
intervals
(CIs).
Heterogeneity
I
statistic.
Results
Of
126
studies,
11
included
from
multiple
countries
diverse
designs.
four
showed
no
statistically
significant
difference
outcomes
users
other
anti‐hyperglycaemic
drugs
(RR:
0.568,
CI:
0.077–4.205).
Substantial
heterogeneity
observed
(I
=
98%).
Pharmacovigilance
indicated
disproportionate
increase
suicidality,
while
some
observational
suggested
a
lower
risk.
Conclusion
found
link
increased
high
reliance
on
pharmacovigilance
data
suggest
caution.
Clinicians
should
monitor
patients,
particularly
those
psychiatric
conditions,
further
research
is
needed
long‐term
safety.
Nutrition in Clinical Practice,
Journal Year:
2025,
Volume and Issue:
unknown
Published: Feb. 17, 2025
Abstract
Incretin
mimetics,
including
glucagon‐like
peptide‐1
and
glucose‐dependent
insulinotropic
polypeptide
agonists,
have
become
first‐line
treatment
options
for
the
of
type
2
diabetes
obesity.
Their
therapeutic
status
is
attributed
to
their
high
level
efficacy
as
well
positive
impact
on
related
comorbidities,
such
sleep
apnea
heart
failure.
Multiple
incretin
mimetics
are
currently
available
with
different
durations
drug
action,
dosing
frequencies,
delivery
devices.
Patients
may
benefit
from
education
proper
administration,
anticipated
adverse
effects,
nutrition
considerations
treatment.
Practitioners
must
monitor
progress
support
patient
achieve
maintenance
doses
optimal
weight
reduction
diabetes‐related
outcomes.
This
review
aims
present
current
literature
supporting
US
Food
Drug
Administration–approved
indications
equip
healthcare
professionals
optimize
care
patients
who
prescribed
these
agents,
provide
insights
into
potential
future
applications,
which
include
dual‐
or
triple‐mechanism
agents
that
injected
administered
orally.
Additional
studies
existing
diabetes,
obesity,
comorbidities
in
a
rapidly
developing
pipeline.
